The acquisition is expected to support Colorcon's product portfolio and its plan to improve health and wellness through convenience, compliance, and safety

Capture-IDC-3-b-e1674120035994

Colorcon acquires Airnov Healthcare Packaging. (Credit: Airnov)

Film coatings and speciality excipients provider Colorcon has closed the acquisition of France-based Airnov Healthcare Packaging from private equity firm Arsenal Capital Partners.

In January this year, Colorcon signed the put agreement to acquire Airnov.

Airnov is engaged in the production of consumables for the protection of healthcare products from moisture and oxygen. It develops high-quality, controlled atmosphere packaging for the critical healthcare sector.

Its product portfolio includes customisable, drop-in products like canisters and packets, integrated desiccant systems and specially designed plastic bottles containing oxygen barrier materials.

With manufacturing facilities in the US, France, China and India, Airnov has global operations and employs around 700 people. The company serves the pharmaceutical, nutraceutical, and diagnostic industries.

Colorcon CEO Simon Tasker said: “Airnov’s capabilities will be a strong complement to Colorcon’s existing portfolio.

“Our partnership will allow for an increased level of technical, customer, and regulatory support to accelerate our customers’ product development and commercialisation.”

The acquisition is expected to support Colorcon’s product portfolio and its plan to improve health and wellness through convenience, compliance, and safety.

Airnov president and managing director Matthias Brommer said: “We are grateful for the support of Arsenal over the past three years as we further established Airnov as the go-to solution provider in the pharmaceutical, nutraceutical, and diagnostic industries.

“We are excited about Airnov’s next phase of growth and our new partnership with Colorcon.”

Colorcon develops, supplies, and provides technical support for speciality ingredients, formulated film coating systems, modified release technologies, and functional excipients.

Its products and technologies are intended to support all phases of solid oral dose design, development, and manufacturing for the pharmaceutical, nutritional, and animal healthcare industries.

US-based company has 11 production plants, 25 technical service laboratories, and employs around 1,400 people.